piperacillin-tazobactam + glycopeptide
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancy
Conditions
Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma, Myeloma, Stem Cell Transplantation
Trial Timeline
Jul 1, 2001 → Mar 1, 2005
NCT ID
NCT00195533About piperacillin-tazobactam + glycopeptide
piperacillin-tazobactam + glycopeptide is a pre-clinical stage product being developed by Pfizer for Hematological Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT00195533. Target conditions include Hematological Malignancy, Leukemia, Myelodysplasia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00195533 | Pre-clinical | Completed |
Competing Products
20 competing products in Hematological Malignancy